Topotecan and cyclophosphamide in adults with relapsed sarcoma

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Blanchette, P ^a   Hogg, D ^b   Ferguson, P ^c   Wunder, J S ^c   Swallow, C ^a   Gladdy, R ^a   Chung, P ^b   Osullivan, B ^b   Blackstein, M E ^b   Catton, C ^b   Gupta, A A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Pediatric Oral and Maxillofacial Surgery   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CAUSE OF DEATH; CLINICAL ARTICLE; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEIOMYOSARCOMA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; RHABDOMYOSARCOMA; SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84864961258     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/749067     Document Type: Article

References (21)

1. Sultan I., Qaddoumi I., Yaser S., Rodriguez-Galindo C., Ferrari A., Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients Journal of Clinical Oncology 2009 27 20 3391 3397
2. Al-Hussaini H., Hogg D., Blackstein M. E., O'Sullivan B., Catton C. N., Chung P. W., Griffin A. M., Hodgson D., Hopyan S., Kandel R., Ferguson P. C., Wunder J. S., Gupta A. A., Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma Sarcoma 2011 2011 7
3. Gupta A. A., Pappo A., Saunders N., Hopyan S., Ferguson P., Wunder J., O'Sullivan B., Catton C., Greenberg M., Blackstein M., Clinical outcome of children and adults with localized ewing sarcoma: impact of chemotherapy dose and timing of local therapy Cancer 2010 116 13 3189 3194
4. Scurr M., Judson I., How to treat the Ewing's family of sarcomas in adult patients Oncologist 2006 11 1 65 72 (Pubitemid 43152688)
5. Womer R. B., West D. C., Krailo M. D., Dickman P. S., Pawel B., Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT) Journal of Clinical Oncology 2008 26 15S supplement, abstract 10504
6. Pommier Y., Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins Seminars in Oncology 1996 23 1, supplement 3 10 (Pubitemid 26117266)
7. Saylors R. L., Stine K. C., Sullivan J., Kepner J. L., Wall D. A., Bernstein M. L., Harris M. B., Hayashi R., Vietti T. J., Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group phase II study Journal of Clinical Oncology 2001 19 15 3463 3469 (Pubitemid 32730082)
8. Walterhouse D. O., Lyden E. R., Breitfeld P. P., Qualman S. J., Wharam M. D., Meyer W. H., Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a children's oncology group study Journal of Clinical Oncology 2004 22 8 1398 1403 (Pubitemid 41103621)
9. Hunold A., Weddeling N., Paulussen M., Ranft A., Liebscher C., Jrgens H., Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors Pediatric Blood and Cancer 2006 47 6 795 800 (Pubitemid 44476756)
10. Bernstein M. L., Devidas M., Lafreniere D., Souid A. K., Meyers P. A., Gebhardt M., Stine K., Nicholas R., Perlman E. J., Dubowy R., Wainer I. W., Dickman P. S., Link M. P., Goorin A., Grier H. E., Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: pediatric oncology group/children's cancer group phase II study 9457a report from the children's oncology group Journal of Clinical Oncology 2006 24 1 152 159 (Pubitemid 46630507)
11. http://www.clinicaltrials.gov/ct2/show/NCT00618813?term=AEWS07P1rank=1, 2011
12. Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) European Journal of Cancer 2009 45 2 228 247
13. Cotterill S. J., Ahrens S., Paulussen M., Jurgens H. F., Voute P. A., Gadner H., Craft A. W., Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group Journal of Clinical Oncology 2000 18 17 3108 3114
14. Park J. R., Scott J. R., Stewart C. F., Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study Journal of Clinical Oncology 2011 29 33 4351 4357
15. Macarulla T., Rodriguez-Braun E., Tabernero J., Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors Journal of Clinical Oncology 2009 27 15S, article 2578
16. McCune J. S., Batchelder A., Deeg H. J., Gooley T., Cole S., Phillips B., Schoch H. G., McDonald G. B., Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality Biology of Blood and Marrow Transplantation 2007 13 7 853 862 (Pubitemid 46902444)
17. McCune J. S., Batchelder A., Guthrie K. A., Witherspoon R., Appelbaum F. R., Phillips B., Vicini P., Salinger D. H., McDonald G. B., Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy Clinical Pharmacology and Therapeutics 2009 85 6 615 622
18. McCune J. S., Salinger D. H., Vicini P., Oglesby C., Blough D. K., Park J. R., Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the children's oncology group Journal of Clinical Pharmacology 2009 49 1 88 102
19. Gupta A. A., Anderson J. R., Pappo A. S., Spunt S. L., Dasgupta R., Indelicato D. J., Hawkins D. S., Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a Report From the Children's Oncology Group Soft Tissue Sarcoma Committee Cancer 2012 118 4 1130 1137
20. Casey D. A., Wexler L. H., Merchant M. S., Chou A. J., Merola P. R., Price A. P., Meyers P. A., Irinotecan and temozolomide for Ewing sarcoma: the memorial sloan-kettering experience Pediatric Blood and Cancer 2009 53 6 1029 1034
21. Wagner L. M., McAllister N., Goldsby R. E., Rausen A. R., McNall-Knapp R. Y., McCarville M. B., Albritton K., Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma Pediatric Blood and Cancer 2007 48 2 132 139 (Pubitemid 44958268)